BTIG Maintains Buy on Viking Therapeutics, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin has maintained a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and increased the price target from $100 to $125.
March 26, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Justin Zelin reaffirmed a Buy rating on Viking Therapeutics and raised the price target from $100 to $125.
The increase in price target by a reputable analyst suggests a strong bullish outlook on Viking Therapeutics, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100